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Abstract
Progranulin haploinsufficiency is associated with frontotemporal dementia in humans. Deficiency of progranulin led to exaggerated
inflammation and premature aging in mice. The role of progranulin in adaptations to nerve injury and neuropathic pain are still unknown.
Here we found that progranulin is up-regulated after injury of the sciatic nerve in the mouse ipsilateral dorsal root ganglia and spinal
cord, most prominently in the microglia surrounding injured motor neurons. Progranulin knockdown by continuous intrathecal spinal
delivery of small interfering RNA after sciatic nerve injury intensified neuropathic pain-like behaviour and delayed the recovery of motor
functions. Compared to wild-type mice, progranulin-deficient mice developed more intense nociceptive hypersensitivity after nerve
injury. The differences escalated with aging. Knockdown of progranulin reduced the survival of dissociated primary neurons and neu-
rite outgrowth, whereas addition of recombinant progranulin rescued primary dorsal root ganglia neurons from cell death induced by
nerve growth factor withdrawal. Thus, up-regulation of progranulin after neuronal injury may reduce neuropathic pain and help motor
function recovery, at least in part, by promoting survival of injured neurons and supporting regrowth. A deficiency in this mechanism
may increase the risk for injury-associated chronic pain.
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Introduction
Progranulin (PGRN) is a cysteine-rich pleiotropic protein affecting
processes as diverse as embryonic development, wound healing,
inflammation, and tumourigenesis [1–4]. PGRN has attracted a
significant attention in the neuroscience research field since 2006,
when loss-of-function mutations of PGRN were discovered as the
cause of familial ubiquitin-positive frontotemporal dementia (FTD)
[5, 6]. A reduction of PGRN by traumatic brain injury may also
increase the risk for FTD [7]. Besides FTD, the plasma level of
PGRN has been suggested to serve as a marker for other neurode-
generative diseases including Alzheimer’s disease [8, 9] or motor
neuron degeneration [10]. Little is known about the role of PGRN
in modulating persistent chronic pain after peripheral or central
nerve injury or degeneration.
PGRN-deficient mice showed behavioural deficits and pro-
gressive neuropathology [11] and signs of premature aging [12].
These mice displayed exaggerated inflammation in the brain, with
greater activation of microglia and astrocytes than their wild-type
counterparts [13]. Because microglia plays a crucial role in the
initiation of neuropathic pain [14–18], we hypothesized that
PGRN may contribute to adaptive processes after nerve injury
and modify the development or maintenance of neuropathic pain.
Here we showed that PGRN expression was up-regulated after
neuronal injury in the spared nerve injury (SNI) model of neuro-
pathic pain. We also found that PGRN deficiency increases noci-
ceptive hypersensitivity after nerve injury and reduces survival
and outgrowth of primary neurons. PGRN may therefore con-
tribute to favourable endogenous adaptations that help to prevent
chronic pain after nerve injury.
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Material and methods
Mice
Male C57BL/6 mice were purchased from the Charles River (Sulzfeld,
Germany). PGRN-deficient (Grn
/) and matched wild-type mice (Grn
/)
were generated as described [13]. Animals had free access to food and
water and were maintained in climate controlled rooms at a 12-hr
light–dark cycle. Behavioural experiments were performed between 
10 a.m. and 1 p.m. The experiments were approved by the local Ethics
Committee for animal research (Darmstadt, Germany), adhered to the
guidelines for pain research in conscious animals of the International
Association for the Study of PAIN (IASP) and are in line with the European
and German regulations for animal research.
Culture of primary dorsal root ganglia (DRG) neurons
Primary adult dissociated DRG neuron-enriched cultures were prepared by
dissecting mouse DRGs into HBSS (Ham’s balanced salt solution;
Dulbecco, GibcoBRL, Karlsruche, Germany) and 10 mM HEPES, followed
by digestion with 5 mg/ml collagenase A and 1 mg/ml dispase II (Roche
Diagnostics, Mannheim, Germany) prior to treatment with 0.25% trypsin
(GibcoBRL, Karlsruhe, Germany). Triturated cells were centrifuged through
a 10% bovine serum albumin solution prior to plating on poly-L-lysine and
laminin-coated cover slips in Neurobasal medium (GibcoBRL) containing
2% (v/v) B27 supplement (GibcoBRL), 50 g/ml Pen-Strep, 10 M Ara-C,
100 ng/ml nerve growth factor (NGF) and 200 mM l-glutamine. After incu-
bation for 2 hrs, 2 ml complete Neurobasal medium was added and neurons
were incubated for 24 hrs. Cells were kept at 37C, 5% CO2, 95% humidity.
Lentivirus particles were added at 1 moi to cultured primary neurons and
incubated for 2–7 days (depending on the experiment) with half exchange
of the medium at 3 days. Lentivirus transduction efficiency was analysed by
enhanced green fluorescent protein (EGFP) immunofluorescence.
Nerve injury
Surgery and injections were done under 1.5–2% isoflurane anaesthesia.
For the SNI model of neuropathic pain, two of the three peripheral
branches of the sciatic nerve, the common peroneal and the tibial nerves,
were ligated with silk (6–0) and distally cut, leaving the sural nerve intact
[19]. For the chronic constriction injury of the sciatic nerve (CCI), the sci-
atic nerve was constricted with three silk ligatures providing about 50%
constriction of the nerve diameter [20]. For the spinal nerve ligation (SNL)
model, the L5 spinal nerve was sectioned. For the crush model the sciatic
nerve was crushed for 25 sec. with a blunt forceps providing constant
pressure without damaging the myelin sheath. In the axotomy model, the
sciatic nerve was ligated and sectioned, proximal to the separation into its
branches. Mechanical and cold pain sensitivity and motor functions were
determined before and after nerve injury up to three months after SNI.
Treatments of interfering RNA (siRNA)
The PGRN small interfering RNA (siRNA) was administered by continuous
intrathecal delivery through a spinal catheter (1.5 pmol, 0.25 l/hr) with a
subcutaneously implanted osmotic pump (Alzet model 2004; Charles River)
for 4 weeks. The control group received corresponding scramble siRNA at
identical infusion rates. Nine mice were used per group. To enable intrathe-
cal delivery at the level of lumbar spinal segments, a polytetrafluoroethylene
catheter (PTFE Sub-Lite Wall Tubing 0.05 mm I.D.  0.15 mm O.D.;
Braintree Scientific Inc., MA, USA) was stereotactically inserted after hemil-
aminectomy at S1–S2 under isoflurane anaesthesia. The tip of the catheter
was positioned few millimetres proximal of L4/5. The intrathecal catheter
was attached to a silicone tube, which was connected to the outlet of the
Alzet mini-pump. The Alzet pump was inserted into the subcutaneous space
at the left flank. Correct positioning of the catheter tip was confirmed at the
end of the treatment period by microscopic inspection. Green BLOCK-iT™
Fluorescent Oligo (Invitrogen, Darmstadt, Germany) was added into siRNA
and controls to visualize the correct delivery.
Nociception and motor functions
All tests were performed by an investigator blinded to the treatments or
mouse genotypes. After habituation, we determined the latency for paw with-
drawal using a Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy)
to assess the sensitivity to mechanical stimulation. The steel rod was pushed
towards the paw with ascending force (0–5 g over a 10 sec. period, 0.2 g/sec.)
and then maintained at 5 g until the paw was withdrawn. The paw withdrawal
latency was the mean of three consecutive trials with at least 30 sec. intervals.
To assess the sensitivity to cold, we recorded the latency of paw lick-
ing or withdrawal on a Cold Plate at 10C (AHP-1200CPHC; Teca, Chicago,
IL, USA). We also analysed cold allodynia employing the acetone test. A
drop of acetone was applied to the plantar surface of the hindpaw with help
of an angled feeding tube. The mouse was sitting on a mesh floor and was
observed with bottom and side mirrors. The time the mouse spent licking,
flinching or shaking the paw was measured with a stopwatch during a
period of 90 sec. starting immediately after acetone application.
Heat hyperalgesia was analysed in the Hargreaves test employing a
radiant heat source placed underneath the paw with help of a mirror sys-
tem (IITC Plantar Analgesia Meter). The heat source shuts off automatically
upon withdrawal of the paw or at a pre-set cut-off time if the animal 
had not responded. The paw withdrawal latency was the mean of three
consecutive trials with at least 30 sec. intervals.
We performed Rota Rod tests at constant speed (60 rpm) to assess sen-
sorimotor functions and motor coordination. The time the animal kept running
was determined with a stopwatch, with 1.5 min. running time as upper limit.
Quantitative RT-PCR (QRT-PCR)
Total RNA was extracted from homogenized tissue according to the proto-
col provided in the RNAeasy tissue Mini Kit (Qiagen, Hilden, Germany), and
Name Start
Sense RNA sequence
5-3
Region GC%
NM_008175_stealth_
349
349
CACUGUAGUGCA-
GAUGGGAAAUCCU
ORF 48
NM_008175_stealth_
control_349
CACGAUCGUAGAG-
GUAAGUAUGCCU
48
NM_008175_stealth_
733
733
CCAAUGCCCAAUGC-
CAUCUGCUGUU
ORF 52
NM_008175_stealth_
control_733
CCACCCGGUAAUACC-
CGUCUUAGUU
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reverse transcribed using poly-dT as a primer to obtain cDNA fragments.
QRT-PCR was performed with an ABI prism 7700 TaqMan thermal cycler
(Applied Biosystems, Germany) using the Sybrgreen detection system with
primer sets detailed later. Specific PCR product amplification was con-
firmed with gel electrophoresis. Transcript regulation was determined
using the relative standard curve method according to the manufacturer’s
instructions (Applied Biosystems). Amplification was achieved at 64C for
35 cycles using two specific primer pairs for mouse PGRN:
pair-1 (spanning nucleotides 169–285; the A of ATG is referred to as
nucleotide no. 1)
forward: 5-CTAGATGGCTCCTGCCAGAC-3; reverse: 5-
GCCATCACCACAAGACACAC-3
pair-2: spanning nucleotides 1817–1955
forward: 5-CCGAGGGTACCCACTACTCA-3; reverse: 5-GCCACAGC-
CTTCTTTCCATA-3
Western blot analysis
Whole cell protein extracts were prepared in RIPA lysis buffer (Sigma,
Steinheim, Germany), containing a protease inhibitor cocktail and 1 mM
PMSF. Spinal cord and DRG tissue samples were homogenized in
PhosphoSafe buffer (Sigma), and protease inhibitor mixture (Complete™ ,
Roche, Germany). Proteins were separated by 12% SDS-PAGE (30 g/lane)
and transferred to nitrocellulose membranes (Amersham Pharmacia
Biotech, Freiburg, Germany) by Western blotting. After blocking in Odyssey
blocking buffer (LI-COR Biosciences, Bad Homburg, Germany), proteins
were detected using the following antibodies directed against: PGRN N19
(N-terminal peptide N19; Santa Cruz Biotechnology, Heidelber, Germany)
detects full-length PGRN and granulins 1, 2 and 7), Hsp90 (Becton
Dickinson, Germany) and -actin (Sigma) and secondary antibodies
  conjugated with IRDye 680 or 800 (1:10,000; LI-COR Biosciences).
Primary antibodies were used at 1:500 dilutions in blocking buffer and
overnight incubation at 4C, secondary antibodies 1:1000 for 2 hrs at room
temperature. To confirm the specificity of the N19 goat PGRN antibody,
antigen-competition was carried out by pre-adsorbing the antibody at
1:500 with the blocking peptide (Santa Cruz Biotechnology) and with
recombinant protein. In further control experiments, the antibody was pre-
absorbed with protein extracts of PGRN knockout mice before use. Blots
were visualized and analysed on the Odyssey Imaging System (LI-COR
Biosciences). The ratio of the respective protein band to the control band
was used for semi-quantitative analysis.
In situ hybridization
Freshly frozen DRGs and spinal cord were cut at 14 m, fixed for 20 min.
in 4% paraformaldehyde (PFA) in 0.1M phosphate buffered saline (PBS)
and acetylated. Sense and anti-sense riboprobes for mouse PGRN
(nucleotides 55–692, length 637) were obtained by cloning PCR products
into the pCR4 TOPO sequencing vector (Invitrogen), and subsequently
subjected to in vitro transcription and labelling with digoxigenin (Dig-labeling
kit, Roche). Sections were pre-hybridized for 2 hrs at room temperature
and hybridized at 70°C for 16 hrs with 200 ng/ml of sense and anti-sense
probes in the pre-hybridization mix (50% formamide, 5 SSC, 5
Denhardt’s solution, 500 g/ml herring sperm DNA, 250 g/ml yeast
tRNA) [21], washed in 0.2% SSC at 60C and incubated with anti–Dig-AP
or anti–Dig-FITC (1:1000, Roche) in 0.12M maleic acid buffer with 0.15M
NaCl, pH 7.5 and 1% Blocking Reagent (Roche), washed in TBS, equili-
brated in alkaline buffer (0.1M Tris-HCl, 0.1M NaCl, 0.05M MgCl2, pH 9.5,
2 mM levamisole), and developed with BM Purple AP substrate (Roche
Diagnostics) or NBT/BCIP (Sigma). Slides were embedded in glycerol/gelatine
or processed for post in situ immunohistochemistry and analysed on a
  fluorescence microscope (AxioImager, Zeiss, Germany).
Immunofluorescence
We perfused terminally anaesthetized mice transcardially with 0.9%
saline followed by 4% PFA in 0.1M PBS (pH 7.4). The L4 and L5 spinal
cord segments and DRGs were dissected and post-fixed for 2 hrs and
then transferred into 20% sucrose in PBS for overnight cryoprotection at
4C. The tissue was embedded in Tissue-Tek
®O.C.T. Compound (Science
Services, Munich, Germany) and cut in transverse sections (10 m for
DRGs, 14 m spinal cord) on a cryotome. Sections were permeabilized
for 5 min. in PBST (0.1% Triton X-100 in 0.1M PBS), blocked for 1 hr
with 1% blocking reagent containing casein (Roche Diagnostics) in
PBST, and incubated overnight at 4C with primary antibodies dissolved
in 1% blocking reagent in PBST. Antibodies directed against PGRN 
(N19, 1F5 from Abnova, Heidelberg, Germany), Iba-1 (Dianova, Hamburg,
Germany), peripherin (Chemicon, Hofheim, Germany), GFAP (Sigma),
ATF-3 (Santa Cruz Biotechnology) and F4/80-Cy5 (Becton Dickinson)
were used. After washes in PBS, we incubated the sections for 2 hrs 
at room temperature with species-specific secondary antibodies
  conjugated with Alexa dyes (Invitrogen) or Cy3 (Sigma). To reduce
  lipofuscin-like autofluorescence slides were briefly immersed in 0.1%
Sudan black B (in 70% ethanol) [22], rinsed in PBS and cover slipped in
antifade medium. Sections were analysed on a fluorescent microscope
(AxioImager).
Generation of PGRN small hairpin RNA (shRNA)
expressing lentiviral constructs
The siRNA sequence was designed as described previously [23]
employing an mRNA sequence of 19–23 nucleotides complimentary to
the target PGRN cDNA [sequence AAG (N18–22) TT]. The first guanine
base is required to recreate the 1 site of the U6 promoter in the lentivi-
ral vector, thereby making it functional for the transcription of shRNAs.
We used the lentiviral vector pLentiLox3.7 (pLL-3.7) [23]. To generate
the pLL-shGrn construct, two complimentary oligonucleotides consi  -
sting of the Grn-siRNA sequence were annealed and inserted into the
HpaI and XhoI sites of pLL-3.7. The oligomer annealing reaction was
performed at an established thermal cycle protocol consisting of 95C
for 2 min., 65C for 10 min., 37C for 10 min., 20C for 20 min. and final
incubation at 4C for 10 min. Each step was run once. We tested three
different siRNAs for progranulin (sequence later). Because progranulin
knockdown was most efficient with siRNA-Grn C (Fig. S1) further 
experiments were carried out with this one. Scramble-shGrn-pLL-3.7
and ‘empty’ pLL-3.7 were used in control experiments. After confirma-
tion that scramble-shGrn did not affect progranulin expression (Fig. S1)
we used ‘empty’ pLL-3.7 as control.
Accession
NM_008175
Sequence of small interfering RNAs Start Region
siRNA-Grn a GGGTGTGTCTTGTGGTGAT 303 ORF
siRNA-Grn b GGCCGTGTGTTGTGAGGATCACA 966 ORF
siRNA-Grn c GGTTGGGAATGTGGAGTGTG 1572 ORFJ. Cell. Mol. Med. Vol 16, No 4, 2012
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Cloning of lentiviral vectors and generation 
of stable cell lines expressing PGRN
To generate lentiviral constructs expressing PGRN, full-length mouse and
human PGRN cDNAs were cloned into a modified lentiviral pLL-3.7 vector
(Fig. S1). The ubiquitin promoter-MCS (multiple cloning site) cassette was
inserted in frame 5’ upstream of the U6 promoter of pLL-3.7 via SpeI and
XhoI sites. The modified pLL-3.7 was kindly provided by Dr. Kwon (Ajou
University, Suwon, South Korea) and referred to as FUMU6W-Lox3.7
(short: pUW-lox3.7). Hence, the backbone of the pLL-3.7 was unaltered so
that the empty pLL-3.7 could be used as control for viruses silencing and
overexpressing PGRN. The pLL-3.7 contains an open reading frame for the
EGFP under a CMV promoter, making identification of transduced cells
straightforward. PGRN cDNA sequences were confirmed by sequencing
using the pCR4 TOPO sequencing vector (Invitrogen) before final sub-
cloning into the lentiviral vector. F11 hybridoma cells and primary sensory
neurons were transduced in foetal calf serum free medium with lentivirus
particles. Transduced cells were cultured for 5 days, harvested in lysis
buffer or RNA extraction buffer and monitored for PGRN expression by
Western blot analysis and RT-PCR.
Virus amplification and production of high-titre
lentivirus stocks
Lentiviral particles were produced by transient cotransfection of HEK
293T cells with pLL-shGrn or pUGrnW-lox3.7 together with three helper
plasmids, pMDL/RRE, RSV-Rev, pMD2G-VSVG, using the calcium–
phosphate method according to standard protocols [23]. For transduc-
tion, 1.8  10
6 293T cells were seeded in 6-cm tissue culture dishes 
the day before transduction. Fresh medium was added 2–4 hrs prior to
precipitation. The transfection mix consisted of 10 g purified endogen-
free DNAs of shGrn-LL3.7 or pUGrnW-lox3.7, 5 g of pMDLg/RRE, 5 g
RSV-Rev and 3 g of pMD2G-VSVG per culture plate. The supernatants
containing lentivirus particles were harvested at 24 and 48 hrs after trans-
duction, passed through a 0.45-m filter, concentrated by ultracentrifuga-
tion at 25,000 rpm for 90 min. at 48°C and resuspended in 20 l 0.1M
PBS. The titre was determined by transducing F11 cells followed by 
flow cytometric analysis of EGFP expression, because the parent vector
pLL-3.7 expressed EGFP (Fig. S1A).
Culture of F11 hybridoma cells
F11 cells are derived by fusion of mouse DRG neurons and mouse neuro  -
blastoma cells and they have maintained several characteristics of primary
DRG neurons [24]. F11 hybridoma cells were cultured in DMEM, 10%
foetal calf serum and 2 mM glutamine. All cells were kept in an incubator
at 37°C, 95% humidity and 5% CO2 atmosphere.
Neurite outgrowth and survival
Neuron cultures were fixed in 4% PFA in 0.1M PBS and detected by
immunostaining for NF200 and subsequent Cy3-labeled secondary anti-
body. Successful lentiviral transduction was assessed by EGFP immuno  -
fluorescence. Neurite outgrowth was determined by measuring the area
covered by neurites, the length of the longest neurite, and total length of all
neurites, the number of central neurites and the area of the cell soma. The
analysis was done using the AutMess modul of AxioVision (Zeiss, Jena,
Germany) and adapted to automatically detect neurites and neuronal 
bodies in collaboration with S.CO LifeScience GmbH (Hohenkirchen,
Germany). Examples of the quality of the identification of neurites and
soma are shown in Figure S2.
Cell survival was assayed by counting the number of surviving neurons
and reported as percent of baseline, taken immediately before transduc-
tion. We captured each four representative images of primary neuronal cul-
tures before transduction and then every 24 hrs up to 5 days until control
cultures showed a substantial decline of the number of surviving neurons.
An inverted AxioImager.Z1 fluorescence microscope was used and cell
counts obtained with AxioVision 4.2 analysis software (AutMess modul).
For starvation experiments in adult primary neurons we replaced the
medium at 2 hrs after plating cells with NGF-free medium with or without
recombinant PGRN (100 ng/ml), NGF (200 ng/ml) or both. Images were
taken daily up to 120 hrs and surviving neurons were counted as
described earlier.
Statistics
We used SPSS 18.0 for statistical evaluation. Data are presented as means
	 S.E.M. Time courses of behavioural data were analysed using ANOVA for
repeated measurements. In case of a significant difference of the time
course between genotypes, differences at individual time points were sub-
sequently assessed with Student’s t-tests employing a Bonferroni correc-
tion of the 
-level for repeated comparisons. Counts of neurons, area of
neurites, QRT-PCR and Western blot results were analysed with Student’s
t-tests (for two groups) or one-way ANOVA and subsequent Bonferroni t-
tests. P  0.05 was considered to be statistically significant.
Results
Up-regulation of PGRN in the spinal cord and DRGs
after sciatic nerve injury
A strong up-regulation of PGRN mRNA was previously observed
in rats in a microarray screen to assess transcriptional changes in
the DRGs and spinal cord after peripheral sciatic nerve injury [25].
We now performed QRT-PCR in mice and confirmed that there
was a statistically significant increase of PGRN mRNA in the L4/5
DRGs and spinal cord ipsilateral to the sciatic nerve lesion after
SNI (Fig. 1A). A protein at 47–48 kD position, detected in the
Western blot using an antibody recognizing PGRN, granulin 1, 2
and 7 and intermediary fragments, was also found increased in
both spinal cord and DRGs after neuron injury (Fig. 1B). The
specificity of this antibody was established by pre-adsorption
experiments (Fig. 1C). It is possible that this is a PGRN partial
degradation product. The same PGRN product was also found up-
regulated after nerve injury in other different sciatic nerve injury
models 7 days after the injury as compared with sham-surgery
controls (Fig. 1D). These include chronic constriction injury
model, spinal nerve ligation model, crush model and axotomy712 © 2011 The Authors
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model. Thus, PGRN up-regulation in response to nerve injuries
seem to be a general phenomenon.
PGRN up-regulation in microglia and neurons
We next used in situ hybridization and immunostaining to identify
the location and the cell types related to the up-regulation of
PGRN. In naïve mice, there was a weak expression of PGRN in
neurons of the spinal cord (Fig. 2A) and the DRG (Fig. 3A), and
very little PGRN was seen in microglia. After nerve injury using
the SNI model, PGRN mRNA was mostly detected in the ipsilat-
eral dorsal and ventral horn neurons and in activated microglia on
the side ipsilateral to the nerve lesion (Figs 2B-D and 4A).
Confocal staining using an antibody against microglia activation
marker Iba-1 identified microglia as important sources of PGRN
up-regulation (Fig. 2G). Interestingly, the highest levels of PGRN
were found in microglia surrounding injured motor neurons that
were identified by ATF-3 and peripherin staining (Fig. 2E and F).
Injured DRGs also expressed an increased level of PGRN 
(Fig. 3B), where small neurons with unmyelinated C-fibres were
identified by staining with isolectin B4-FITC (IB4) and injured
neurons by anti–ATF-3. Roughly 50–60% of all DRGs neurons
were PGRN positive, consistent with the number of injured 
neurons in the SNI model [21]. In addition, we observed a strong
PGRN up-regulation in satellite glial cells (SGC) in the DRGs 
(Fig. 3C and D), SGCs were identified by their morphology, F4/80
and Iba-1 immunofluorescence (not shown). These findings 
suggest that microglia surrounding injured neurons are the major
source of up-regulated PGRN.
PGRN gene silencing intensified nociception 
and impaired motor function recovery
Given the strong up-regulation of PGRN in DRGs and spinal
cord after injury, we hypothesized that PGRN up-regulation may
be an important mechanism of endogenous pain defence. To
assess the effect of PGRN down-regulation on nociceptive sen-
sitivity after injury, we subjected mice to SNI. Then the injured
mice were divided into two groups. One received continuous
intrathecal delivery of PGRN siRNA for 4 weeks through a spinal
catheter using a subcutaneously implanted osmotic pump. The
control group received scramble oligos in the same fashion.
Fig. 1 Up-regulation of PGRN expression in spinal cord (SC) and dorsal root ganglia (DRG) after nerve injury. (A) Time course of mRNA levels of PGRN
in the L4/L5 DRGs and the L4/5 dorsal horn of the lumbar spinal cord ipsilateral to a sciatic nerve lesion in the SNI model by QRT-PCR (n  3 per group).
(B) Western blot analysis of PGRN in mouse SC and DRGs (n  6 per time point) using anti-PGRN (N19); densitometric analysis is shown on the right
panel. (C) Western blot analysis of PGRN in the spinal cord in naïve and SNI treated mice with N19 pre-absorbed with recombinant PGRN. (D) Western
blot analysis of PGRN in the spinal cord seven days after sciatic nerve injury in five different injury models (n  4 per model). Ax: sciatic nerve transec-
tion (axotomy). SNL: spinal nerve ligation; CCI: chronic constriction injury. Densitometric analysis is shown on the right. Results are mean 	 S.E.M. 
*P  0.05; **P  0.01; ANOVA and subsequent Bonferroni t-tests.J. Cell. Mol. Med. Vol 16, No 4, 2012
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PGRN siRNA effectively blocked the up-regulation of PGRN in
the spinal cord, as determined by QRT-PCR and in situ
hybridization (Fig. 4A). Nociceptive sensitivity was compared
between PGRN siRNA treated and scramble-siRNA treated mice.
The mice receiving PGRN siRNA showed heightened hyperalge-
sia, that is they were more sensitive to mechanical stimulation
(Fig. 4B), spent more time licking, flinching or shaking their
paws in response to acetone (Fig. 4C), and spent less time on a
cold plate before withdrawing their paws (Fig. 4D). The pro-
nociceptive effects of PGRN-knockdown were evident throughout
the second to fourth week of the testing period and escalated
towards the end. The differences in the nociceptive behaviour
between siRNA treated and scramble-siRNA control groups
were significant for all tests (NM_008175_stealth_349 versus
control: mechanical P  0.001; acetone P  0.001; Cold Plate
P  0.026), although endogenous PGRN did not affect the
onset (day 3 after SNI) of injury-induced hyper-nociception.
Similar results were obtained with NM_008175_stealth_733
versus control (not shown).
We also assessed effects of PGRN silencing on motor function
recovery and compensation after sciatic nerve injury in the SNI
model (Fig. 4E). In the Rota Rod test, the initial drop of the run-
ning time after nerve injury did not differ between PGRN siRNA
and scramble-siRNA treated mice. However, control mice rapidly
regained running performance with almost complete recovery 
30 days after SNI. Mice treated with PGRN siRNA only reached
partial recovery within this period. The motor function recovery
differed significantly between the two groups (P  0.003). These
findings suggest that PGRN has a beneficial role in motor neuron
survival and function after axonal injury.
Late onset of hypernociception and impaired
motor recovery in PGRN-deficient mice
siRNAs sometimes can have off-target effects [26]. To confirm
that observed intensified nociception and impaired motor function
recovery after injury directly resulted from a PGRN-deficiency, we
Fig. 2 Up-regulation of PGRN expression in
mouse spinal cord 7 days after SNI. (A–F) In
situ hybridization of PGRN mRNA in L5
spinal cord (A, B), ipsilateral dorsal (C) and
ventral horn (D–F) from naïve (A) or injured
(B–F) mice. Arrows indicate motor neurons
(D) and surrounding microglia (F). Injured
motoneurons were identified by immunore-
activity with ATF-3 (red in E) or peripherin
(red in F). (G) Co-staining of PGRN (red)
and microglia activation marker Iba-1
(green) in the ventral horn of injured mice.
Representative images of n  5 mice. Scale
bars: 500 m (A, B), 50 m (C–E), 20 m
(F) and 10 m (G).714 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
then tested mice with homozygous Grn gene deletion. Adult
PGRN knockout mice and their age- and sex-matched wild-type
controls were subjected to SNI, and compared for their responses
to mechanical or cold allodynia (Fig. 5A and B), heat hyperalgesia
(Fig. 5C) and performance in the RotaRod test (Fig. 5D). The base-
line nociceptive sensitivity and RotaRod running performance did
not differ between PGRN-deficient and wild-type mice. Their noci-
ceptive behaviour in the first 2 weeks after SNI was also similar.
However PGRN-deficient mice developed stronger sensitivity to
mechanical (Fig. 5A), cold (Fig. 5B) and heat stimulation (Fig. 5C)
than wild-type mice starting about 3 weeks after the nerve injury.
The differences persisted and escalated towards the end the
observation period, when these mice were 6–7 months old.
Statistically, nociceptive sensitivity after SNI was enhanced in
PGRN-deficient mice for mechanical (F11.8, df1, P  0.0009),
heat (F4.07, df1, P  0.0464) and cold (F13.6, df1, P  0.0004)
stimulation (Fig. 5) as compared with wild-type controls. In addi-
tion, motor function recovery after SNI was significantly impaired
in PGRN-deficient mice (Fig. 5D). Wild-type mice recovered their
motor function one week after the injury, whereas the recovery of
the PGRN-deficient mice only reached 50% and became worse
seven weeks after injury. ANOVA for repeated measurements
revealed significant differences between the two genotypes
(F12.71, df1, P  0.0006).
PGRN down-regulation by RNA interference
reduced survival of primary sensory neurons
To probe the mechanisms of PGRN-mediated anti-nociceptive
effects, we altered PGRN levels in primary DRG neurons and
assessed their survival and growth. Down-regulation and up-
regulation of PGRN was achieved by transduction of primary
neurons with lentiviral particles expressing PGRN shRNA
(shGrn-LL3.7 a, b and c) or PGRN cDNA (pUGrnW-lox3.7; 
Fig. S1A). We tested three different PGRN shRNA constructs
(Fig. S1). The efficacy of PGRN silencing or up-regulation with
these lentiviral particles was confirmed in cultured F11
hybridoma cells at both mRNA and protein levels (Fig. S1B–D).
Down-regulation of PGRN was most effective with shGrn-
LL3.7c. We therefore used this construct for further experi-
ments in primary neurons. Although knockdown of PGRN with
shGrn-LL3.7c was very effective, increase in PGRN expression
with pUGrnW-lox3.7 was only moderate. Because the parental
viral vector pLL-3.7 expressed EGFP, transduction efficiency
was determined by fluorescence staining. In primary mouse
DRG neuron culture, 80–90% of NF200 positive cells expressed
EGFP (Fig. 6A). shGrn-transduced cultures presented with a
network of thin neurites extending from neurons with small
somata (Fig. 6A). Representative life images of the DRG 
Fig. 3 Up-regulation of PGRN expression in
dorsal root ganglia seven days after SNI. In
situ hybridization of PGRN mRNA in naïve
(A, C) and injured (B, D) mice. Unmyelinated
neurons were detected with isolectin B4-
FITC (IB4, green) and injured neurons were
identified by immunostaining with anti-ATF-
3 (red) (A, B). Arrows in (D) point to satel-
lite glial cells with up-regulated PGRN after
SNI. Representative images of n  5 mice.
Scale bars: 100 m (Aand B, left panel), 50 m
(A and B, right three panels), 20 m (C, D).J. Cell. Mol. Med. Vol 16, No 4, 2012
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cultures 48 hrs after tranduction are shown (Fig. 6B). Primary
neuron numbers declined in the culture (Fig. 6C). Transduction
with viruses facilitated this decline, which was not rescued by
forced expression of PGRN (Fig. 6B and C). The inactivity of
transduction with pUGrnW-lox3.7 viruses may be, in part, due
to their limited PGRN overexpression (Fig. 1B and D). Down-
regulation of PGRN, however, significantly reduced the number
of surviving neurons as compared with neurons treated with
control viral particles (Fig. 6A–C). We next asked whether
recombinant PGRN could rescue adult primary DRG neurons
after NGF withdrawal. In the culture, the numbers of surviving
neurons were reduced by 75–80% compared to the baseline 96
hrs after NGF withdrawal (Fig. 6D). Recombinant human PGRN
completely restored the survival of these neurons in the
absence of NGF, whereas the combination of NGF plus recombi-
nant PGRN provided no further benefit.
Fig. 4 Silencing of PGRN enhanced pro-
nociceptive behaviour after nerve injury.
Adult male C57BL/6 mice were subjected 
to SNI as described in Material and 
methods. Mice then received continuous
intrathecal delivery of PGRN siRNA or
scramble oligos for four weeks (n  9 per
group) through a spinal catheter using a
subcutaneously implanted osmotic pump.
(A) Silencing of PGRN by siRNA in vivo.
PGRN levels were measured by QRT-PCR 
(n  6) (left) or in situ hybridization (right)
of the L5 spinal cord in 15-weeks old male
mice treated with scramble RNAi or PGRN
siRNA for four weeks (NM_008175_
stealth_349). Mice were tested for their
nociceptive behaviour to mechanical stimu-
lation (B), for cold allodynia (C), or cold
hyperalgesia (D) and motor functions in the
RotaRod test (E) as described in Material
and methods. Comparison of the time
courses (ANOVA for repeated measurements)
revealed statistically significant 
differences between groups for all tests. 
The asterisks indicate significant time points
(P  0.05).716 © 2011 The Authors
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Suppression of PGRN expression impaired neurite
outgrowth
Axonal regeneration after injury is an indispensable component of
a successful healing process. To test whether PGRN has a role in
the axonal regeneration, we examined the neurite outgrowth in
adult primary DRG neurons after injury under PGRN silencing or
overexpression. Dissociated primary adult DRG neurons were cul-
tured for 24 hrs to allow for initiation of neurite outgrowth.
Cultured neurons were then transduced with lentiviral particles to
silence or express PGRN. Figure 7A shows representative images
of transduced neurons from each group. The length, width and
area of the neurites and soma were scored with help of the ima  -
ging analysis software (S.CO LifeScience) and comparison was
made between neurons transduced with different viral particles.
Figure S2 shows examples of the quality of the automatic identifi-
cation of neurites and soma from which quantitative data of
length, width and area of the neurites and soma were computed.
We analysed exclusively growing neurons 2 days after transduc-
tion. Quantification revealed that silencing of PGRN led to a statis-
tically significant reduction of the overall number and length of
neurites and the area of the neuronal somata (Fig. 7A and B). In
contrast, overexpression of PGRN resulted in enhanced neurite
outgrowth (Fig. 7A and B). Transduction with empty vector 
pLL-3.7 or scramble-shRNA lentivirus (not shown) had no signifi  -
cant effect on neuron survival or neurite outgrowth as compared
to untransduced DRG cultures.
Discussion
To our knowledge, this study is the first to show that progranulin
has a role in neuropathic pain defense. Peripheral or central nerve
injury or degeneration is a frequent cause of persistent chronic,
pathological pain. Particularly, the elderly have a high risk of
Fig. 5 Progranulin-deficient (Grn
/) mice
showed stronger nociceptive sensitivity after
nerve injury than wild-type mice. PGRN
knockout (Grn
/) mice and their wild-type
control mice (n  8 per group, four male,
four female, 10–12 weeks at the time of 
surgery) were tested for their mechanical
allodynia (A), cold allodynia (B), heat 
hyperalgesia (C) and motor functions (D) as
in Figure 4. Data are means 	 S.E.M.
Comparison of the results with ANOVA
revealed statistically significant differences
between Grn
/ and wild-type mice for the
percentage change of mechanical, cold 
and heat nociception and for the RotaRod
running time as indicated with asterisks 
(P  0.05).J. Cell. Mol. Med. Vol 16, No 4, 2012
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post-zoster, ischaemic or metabolic neuralgias with persistent and
substantial impairment of quality of life. A loss of axonal transport
of growth factors from the peripheral target region to the soma of
a sensory neuron contributes to the death of subsets of primary
and secondary neurons [27–30]. Surviving neurons develop a
state of hyperexcitability and enhancement of the synaptic trans-
mission of nociceptive input [31], giving rise to the development
of neuroinflammation [17] and neuropathic pain [14,18].
Endogenous mechanisms that attenuate or prevent secondary
neuronal damage are essential to regain synaptic stability and to
prevent the development of irreversible nociceptive hypersensitiv-
ity. It is still incompletely understood why neuropathic pain per-
sists in some people and why this risk increases with age.
We showed in this study that injury to the peripheral nerve
increased PGRN expression in injured neurons and glial cells at
both the mRNA and protein levels. Our findings are consistent
Fig. 6 PGRN promotes survival of primary DRG neurons in the culture. (A) Immunofluorescence staining of primary DRG neurons transduced with 
indicated lentivirus particles and counterstained for neurofilament of 200 kD (red, NF200) and EGFP (green). (B) Representative life images of primary
DRG cultures 48 hrs after transduction with indicated lentiviral particles. (C) Time courses of percentage survival of adult primary DRG neuron cultures
(n  4 cultures per treatment) after transduction with indicated viruses. Asterisks indicate significant differences between shGrn versus control virus
(pLL-3.7), P  0.05. (D) Numbers of surviving primary DRG neurons 96 hrs after NGF withdrawal from the culture medium, with or without recombinant
human PGRN, as measured by counting the number of surviving neurons and expressed as percentage of baseline, taken immediately before transduction.
At baseline images captured 298 	 17 neurons per microscopic field. Data are means 	 S.E.M. of triplicates. Asterisks indicate significant differences
versus NGF-free/PGRN-free cultures, P  0.05. ANOVA with subsequent Bonferroni t-tests.718 © 2011 The Authors
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with the report by Matzilevich et al. that PGRN was up-regulated
in a high-density microarray analysis of hippocampal gene expres-
sion following traumatic brain injury [32]. We found that
microglial cells surrounding the injured neurons were the major
source of up-regulated PGRN in the SNI model, which is reminis-
cent of the effect seen after axotomy of motor neurons [33], or in
the mid-thoracic contusion spinal cord injury model [34]. These
authors found elevated levels of PGRN throughout the injury epi-
centre, and co-localization of PGRN staining with myeloid cell
marker CD11b and CD68. In addition, we observed a strong PGRN
up-regulation in SGC in the DRGs. These cells have been sug-
gested to be activated after nerve injury [35–37]. Although 
considered as originated from the neuroectoderm, SGC resemble
microglia and dendritic cells in the expression of myeloid marker
proteins such as Iba-1 and CD11b [38] and might act as PGRN-
secreting cells.
Up-regulation of PGRN after injury appears to be physiologi-
cally important at least for endogenous pain defense. When this
up-regulation was abolished by RNA interference or Grn gene
deletion, we found injury-induced late-phase nociception becom-
ing much intense and the recovery of motor functions delayed.
Thus, an enhanced production of PGRN likely constitutes an
Fig. 7 PGRN supports neurite outgrowth from primary adult DRG neurons in vitro. (A) Representative images demonstrate the morphology of neurons
transduced with lentivirus particles expressing pUmGrn-lox3.7 (PGRN overexpression), shGrn-pLL3.7c (PGRN silencing) or empty vector pLL-3.7.
Neurons were immunostained with anti-NF200. (B) Quantitative analysis of the length and number of neurites and the area of the neurites. Only 
EGFP positive neurons extending neurites of 
two fold length of the neuronal soma diameter were analysed. The results are shown as box plots where
the line indicates the median, the box the interquartile range, whiskers 5–95
th percentile and open dots individual outliers (n  15–19 neurons per group).
*P  0.05, ANOVA with subsequent Bonferroni t-tests.J. Cell. Mol. Med. Vol 16, No 4, 2012
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